RecruitingNCT07101094

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Sponsor

Bristol-Myers Squibb

Enrollment

300 participants

Start Date

Sep 22, 2025

Study Type

OBSERVATIONAL

Conditions

Schizophrenia

Summary

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking how well a newer schizophrenia medication called KarXT (xanomeline-trospium) works in real-world settings, including how satisfied patients are with the treatment. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of schizophrenia - Your doctor has just prescribed you KarXT for the first time and you plan to start taking it - You can read and speak English or Spanish - You are willing to use a phone or computer to report how you're feeling over time **You may NOT be eligible if...** - You have taken KarXT before - You are currently enrolled in another clinical trial or plan to join one soon Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGxanomeline and trospium chloride (X/T) therapy

According to the product label

Locations(18)

Local Institution - 0009

Orange, California, United States

Lumos Clinical Research Center

San Jose, California, United States

Local Institution - 0003

Evanston, Illinois, United States

Local Institution - 0007

Baltimore, Maryland, United States

Local Institution - 0017

Bel Air, Maryland, United States

Local Institution - 0004

Catonsville, Maryland, United States

Local Institution - 0008

Belmont, Massachusetts, United States

Local Institution - 0002

Boston, Massachusetts, United States

Mayflower Clinical

South Dartmouth, Massachusetts, United States

Omaha Insomnia and Psychiatric Services

Omaha, Nebraska, United States

Hackensack Meridian Health - Carrier Clinic

Belle Mead, New Jersey, United States

Local Institution - 0015

New York, New York, United States

New Dawn Psychiatric Services, PLLC

Kinston, North Carolina, United States

Local Institution - 0018

Rose Hill, North Carolina, United States

Westlake Brain Health

Westlake, Ohio, United States

Continuum Health Providers

Fort Mill, South Carolina, United States

Local Institution - 0012

El Paso, Texas, United States

Local Institution - 0013

Longview, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07101094

Related Trials

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT074679937 locations

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

NCT0737982745 locations

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT0722187714 locations

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT071858156 locations

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT057785911 location